SCHEMBL5142907

SCHEMBL5142907

CC(C)(C)OC(=O)NCc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.47
EPHX2 P34913 2/20 0.47
TP53 P04637 1/20 0.46
CACNA1H O95180 1/20 0.46
CACNA1B Q00975 1/20 0.46
CACNA1C Q13936 1/20 0.46
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 2/20 0.42
TRPV1 Q8NER1 1/20 0.42
DDR1 Q08345 1/20 0.42
KDM4A O75164 1/20 0.41
IDO1 P14902 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
RIPK1 Q13546 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664091 0.84 CACNA1H (0.46) CACNA1HCACNA1BCACNA1CDDR1KDM4A
SCHEMBL27988801 0.83 IDO1 (0.53) P2RX7EPHX2TP53MAPTDDR1
SCHEMBL27649206 0.83 CACNA1H (0.45) EPHX2CACNA1HCACNA1BCACNA1CTRPV1
SCHEMBL31704494 0.82 CACNA1H (0.46) EPHX2CACNA1HCACNA1BCACNA1CTRPV1
SCHEMBL5413105 0.81 EPHX2 (0.48) EPHX2KDM4AIDO1NR1H4KDM4E
SCHEMBL30101811 0.81 KDM4A (0.43) KDM4AIDO1KDM4EALDH1A1
SCHEMBL2520675 0.81 AAK1 (0.46) DDR1KDM4AIDO1FPR3FPR2
SCHEMBL31142926 0.81 AAK1 (0.46) DDR1KDM4AIDO1FPR3FPR2
SCHEMBL5144626 0.80 P2RX7 (0.55) P2RX7EPHX2TP53MAPTNR1H4
SCHEMBL2553317 0.79 KDM4A (0.41) KDM4AIDO1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7301022-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-11-27 US disclosed
US-7301022-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-11-27 US disclosed
US-7301022-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-11-27 US disclosed
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 P2RX7 616/4885EPHX2 4341/4885TP53 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.